JP7209637B2 - 自己免疫性水疱症の治療のためのコバーシン - Google Patents

自己免疫性水疱症の治療のためのコバーシン Download PDF

Info

Publication number
JP7209637B2
JP7209637B2 JP2019556794A JP2019556794A JP7209637B2 JP 7209637 B2 JP7209637 B2 JP 7209637B2 JP 2019556794 A JP2019556794 A JP 2019556794A JP 2019556794 A JP2019556794 A JP 2019556794A JP 7209637 B2 JP7209637 B2 JP 7209637B2
Authority
JP
Japan
Prior art keywords
seq
sequence
agent
protein
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517627A (ja
JP2020517627A5 (https=
Inventor
アンドリュー ナン，マイルズ
アビヤンカー，ブリハッド
デイヴィッド サディク，クリスチャン
Original Assignee
ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706404.9A external-priority patent/GB201706404D0/en
Priority claimed from GBGB1706452.8A external-priority patent/GB201706452D0/en
Application filed by ヴォリューション イミュノ ファーマシューティカルズ エスエイ filed Critical ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Publication of JP2020517627A publication Critical patent/JP2020517627A/ja
Publication of JP2020517627A5 publication Critical patent/JP2020517627A5/ja
Priority to JP2023001554A priority Critical patent/JP7600278B2/ja
Application granted granted Critical
Publication of JP7209637B2 publication Critical patent/JP7209637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019556794A 2017-04-21 2018-04-20 自己免疫性水疱症の治療のためのコバーシン Active JP7209637B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023001554A JP7600278B2 (ja) 2017-04-21 2023-01-10 自己免疫性水疱症の治療のためのコバーシン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706404.9 2017-04-21
GB1706406.4 2017-04-21
GBGB1706404.9A GB201706404D0 (en) 2017-04-21 2017-04-21 Method of treatment
GBGB1706452.8A GB201706452D0 (en) 2017-04-24 2017-04-24 Method of treatment
GB1706452.8 2017-04-24
PCT/EP2018/060241 WO2018193122A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023001554A Division JP7600278B2 (ja) 2017-04-21 2023-01-10 自己免疫性水疱症の治療のためのコバーシン

Publications (3)

Publication Number Publication Date
JP2020517627A JP2020517627A (ja) 2020-06-18
JP2020517627A5 JP2020517627A5 (https=) 2021-05-27
JP7209637B2 true JP7209637B2 (ja) 2023-01-20

Family

ID=62235916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556794A Active JP7209637B2 (ja) 2017-04-21 2018-04-20 自己免疫性水疱症の治療のためのコバーシン
JP2023001554A Active JP7600278B2 (ja) 2017-04-21 2023-01-10 自己免疫性水疱症の治療のためのコバーシン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023001554A Active JP7600278B2 (ja) 2017-04-21 2023-01-10 自己免疫性水疱症の治療のためのコバーシン

Country Status (12)

Country Link
US (2) US11730792B2 (https=)
EP (2) EP3612208B1 (https=)
JP (2) JP7209637B2 (https=)
KR (1) KR102656199B1 (https=)
CN (1) CN110896606B (https=)
AU (1) AU2018253962B2 (https=)
CA (1) CA3059657A1 (https=)
DK (1) DK3612208T5 (https=)
ES (1) ES2945433T3 (https=)
IL (1) IL269895B2 (https=)
PL (1) PL3612208T3 (https=)
WO (1) WO2018193122A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) * 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
GB202218084D0 (en) * 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100396A1 (en) 2009-02-05 2010-09-10 Natural Environment Research Council Modified omci as a complement inhibitor
WO2010151526A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4772667B2 (ja) 2003-06-02 2011-09-14 エヴォルーテック・リミテッド 補体阻害剤
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2007095230A2 (en) 2006-02-13 2007-08-23 The Trustees Of The University Of Pennsylvania TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
JP2010521194A (ja) 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
JP2012505160A (ja) * 2008-10-06 2012-03-01 カロラス セラピューティクス， インク． 炎症を処置する方法
AU2011204483B2 (en) 2010-01-08 2016-02-11 Volution Immuno Pharmaceuticals Sa EV576 for use in the treatment of viral infections of the respiratory tract
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410031D0 (en) 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
CA2988313A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP4365291A3 (en) 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2017044811A1 (en) 2015-09-11 2017-03-16 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100396A1 (en) 2009-02-05 2010-09-10 Natural Environment Research Council Modified omci as a complement inhibitor
WO2010151526A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5

Also Published As

Publication number Publication date
US11730792B2 (en) 2023-08-22
US20240009270A1 (en) 2024-01-11
JP2020517627A (ja) 2020-06-18
IL269895B1 (en) 2024-02-01
ES2945433T3 (es) 2023-07-03
AU2018253962B2 (en) 2024-12-05
US20200113971A1 (en) 2020-04-16
AU2018253962A1 (en) 2019-10-31
WO2018193122A1 (en) 2018-10-25
IL269895B2 (en) 2024-06-01
EP3612208A1 (en) 2020-02-26
CA3059657A1 (en) 2018-10-25
DK3612208T5 (da) 2024-09-02
EP4275696A1 (en) 2023-11-15
KR102656199B1 (ko) 2024-04-09
PL3612208T3 (pl) 2023-07-24
KR20190139233A (ko) 2019-12-17
JP7600278B2 (ja) 2024-12-16
IL269895A (https=) 2019-12-31
CN110896606B (zh) 2024-07-16
CN110896606A (zh) 2020-03-20
EP3612208B1 (en) 2023-04-05
JP2023040169A (ja) 2023-03-22
DK3612208T3 (da) 2023-05-08

Similar Documents

Publication Publication Date Title
JP7209637B2 (ja) 自己免疫性水疱症の治療のためのコバーシン
TWI784988B (zh) 治療發炎症狀的方法
RU2700932C2 (ru) Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента
JP7153669B2 (ja) 瘢痕性眼炎症障害の治療のためのコバーシン
US20250195612A1 (en) Coversin for use in the treatment of rheumatic diseases
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230110

R150 Certificate of patent or registration of utility model

Ref document number: 7209637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150